Aimed Bio Inc. (KOSDAQ:0009K0)

South Korea flag South Korea · Delayed Price · Currency is KRW
51,900
-600 (-1.14%)
At close: Feb 26, 2026
17.95%
Market Cap 3.98T
Revenue (ttm) 29.65B
Net Income (ttm) -43.02B
Shares Out 64.67M
EPS (ttm) -1,065.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 262,986
Average Volume 448,741
Open 52,800
Previous Close 52,500
Day's Range 51,300 - 52,800
52-Week Range 42,000 - 80,200
Beta n/a
RSI 63.25
Earnings Date Mar 30, 2026

About Aimed Bio

Aimed Bio Inc. develops therapeutic solutions for patients with brain diseases, including neuro-oncological and degenerative diseases. Its multidisciplinary platform offers antibody-drug conjugates, blood-brain barrier penetration, brain immune modulation, and patient-derived models (PDC/PDX). Aimed Bio Inc. was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 0009K0
Full Company Profile

Financial Performance

In 2024, Aimed Bio's revenue was 11.76 billion, an increase of 6768.70% compared to the previous year's 171.21 million. Losses were -3.30 billion, -63.38% less than in 2023.

Financial Statements

News

There is no news available yet.